Segment and Geographic Information - Schedule of Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Revenue	$ 181,398	$ 100,049	$ 302,314	$ 180,727
Selling and marketing expense	42,260	38,710	82,089	78,319
General and administrative expense	64,367	41,068	116,486	85,422
Research and development expense	25,047	24,787	48,114	59,164
Interest income	1,618	2,640	2,121	4,408
Interest expense	(19,208)	(13,674)	(31,990)	(22,964)
Changes in fair value of financial instruments	(17,870)	12,000	(50,203)	936
Other expense, net	(18,341)	(141)	(18,358)	(360)
Net loss	(71,790)	(66,186)	(174,370)	(177,214)
Reportable Segment
Revenue	181,398	100,049	302,314	180,727
Selling and marketing expense	42,260	38,710	82,089	78,319
General and administrative expense	64,367	41,068	116,486	85,422
Research and development expense	25,047	24,787	48,114	59,164
Interest income	1,618	2,640	2,121	4,408
Interest expense	(19,208)	(13,674)	(31,990)	(22,964)
Changes in fair value of financial instruments	(17,870)	12,000	(50,203)	936
Other expense, net	(18,341)	(141)	(18,358)	(360)
Net loss	(71,790)	(66,186)	(174,370)	(177,214)
Molecular Profiling Services
Revenue	162,924	87,656	277,006	160,890
Cost of services	65,321	59,431	126,215	112,324
Molecular Profiling Services | Reportable Segment
Cost of services	65,321	59,431	126,215	112,324
Pharma Research And Development Services
Revenue	18,474	12,393	25,308	19,837
Cost of services	2,392	3,064	5,350	4,732
Pharma Research And Development Services | Reportable Segment
Cost of services	$ 2,392	$ 3,064	$ 5,350	$ 4,732